Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 08, 2021, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Selexipag Tablets, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,400 mcg, and 1,600 mcg".